<DOC>
	<DOCNO>NCT01356108</DOCNO>
	<brief_summary>The purpose registry retrospectively prospectively obtain clinical data consecutively treat patient , order demonstrate commercially available Edwards SAPIEN Valve RF3 delivery system safe effective treatment patient pulmonary regurgitation stenosis .</brief_summary>
	<brief_title>Pulmonic Valve REplacement Multi-discIpline EMEA Registry</brief_title>
	<detailed_description>Consecutive patient data collect discharge , 6 month , 12 month 2-5 year post-implant .</detailed_description>
	<mesh_term>Pulmonary Valve Stenosis</mesh_term>
	<mesh_term>Pulmonary Valve Insufficiency</mesh_term>
	<mesh_term>Respiratory Insufficiency</mesh_term>
	<criteria>Symptomatic regurgitant stenotic pulmonary valved conduit . Angiographic evidence coronary artery compression . RVPA pulmonary conduit size either large small accommodate SAPIEN THV . Thrombus intracardiac mass right atrium , right ventricle , and/or pulmonic valve . Severe coagulation problem and/or unable tolerate anticoagulation/antiplatelet therapy . Active bacterial endocarditis active infection . Illeofemoral venous stenosis may prevent placement introducer sheath and/or central venous vascular tortuosity may prevent advancement delivery system heart pulmonary artery . Presence prosthetic valve tricuspid position . Unstable coronary artery diseaserelated angina . Placement SAPIEN THV pregnant female .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Conduit</keyword>
	<keyword>Pulmonic</keyword>
	<keyword>Stenosis</keyword>
	<keyword>Regurgitation</keyword>
	<keyword>Dysfunctional</keyword>
</DOC>